Table 1.
Baseline Characteristics in the Study Sample vs the Original JUPITER Cohort
| Characteristic | Current JUPITER Substudy (N=9423) | Overall JUPITER Trial (N=17 802) |
|---|---|---|
| Age, y | 66 (60, 71) | 66 (60, 71) |
| Women | 36 | 38 |
| Rosuvastatin | 49 | 50 |
| Race/ethnicitya | ||
| White | 85.1 | 71.2 |
| Black | 5.2 | 12.5 |
| Asian | 1.5 | 1.6 |
| Hispanic | 7.5 | 12.7 |
| Other/unknown | 0.7 | 1.96 |
| Body mass index, kg/m2 | 28.5 (25.6, 32.0) | 28.3 (25.3, 32.0) |
| Hypertension | 56 | 57 |
| Systolic blood pressure, mm Hg | 134 (124, 146) | 134 (124, 145) |
| Diastolic blood pressure, mm Hg | 80 (75, 86) | 80 (75, 87) |
| Current smoker | 14 | 16 |
| Family history of premature coronary disease | 13 | 11 |
| Glucose, mg/dL | 95 (89, 102) | 94 (88, 102) |
| hsCRP, mg/L | 4.05 (2.75, 6.65) | 4.25 (2.85, 7.10) |
| LDL‐C, mg/dL | 109 (96, 119) | 108 (94, 119) |
| Apolipoprotein B, mg/dL | 109 (97, 122) | 109 (95 122) |
| Triglycerides, mg/dL | 119 (88, 169) | 118 (85, 169) |
| HDL‐C, mg/dL | 49 (41, 60) | 49 (40, 60) |
Values shown are median (25th, 75th percentile) or proportion (%). HDL‐C indicates high‐density lipoprotein cholesterol; hsCRP high‐sensitivity C‐reactive protein; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin trial; LDL‐C, low‐density lipoprotein cholesterol.
a
Proportions do not sum to 100% given rounding.